- Home
- HOND vs NKTR Comparison
HOND vs NKTR Comparison
Compare HOND & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOND
- NKTR
- Stock Information
- Founded
- HOND 2024
- NKTR 1990
- Country
- HOND United States
- NKTR United States
- Employees
- HOND N/A
- NKTR N/A
- Industry
- HOND
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- HOND
- NKTR Health Care
- Exchange
- HOND NYSE
- NKTR Nasdaq
- Market Cap
- HOND 287.5M
- NKTR 247.9M
- IPO Year
- HOND 2024
- NKTR 1994
- Fundamental
- Price
- HOND $10.00
- NKTR $1.26
- Analyst Decision
- HOND
- NKTR Buy
- Analyst Count
- HOND 0
- NKTR 5
- Target Price
- HOND N/A
- NKTR $4.00
- AVG Volume (30 Days)
- HOND 1.0K
- NKTR 1.6M
- Earning Date
- HOND 01-01-0001
- NKTR 11-07-2024
- Dividend Yield
- HOND N/A
- NKTR N/A
- EPS Growth
- HOND N/A
- NKTR N/A
- EPS
- HOND N/A
- NKTR N/A
- Revenue
- HOND N/A
- NKTR $93,137,000.00
- Revenue This Year
- HOND N/A
- NKTR N/A
- Revenue Next Year
- HOND N/A
- NKTR N/A
- P/E Ratio
- HOND N/A
- NKTR N/A
- Revenue Growth
- HOND N/A
- NKTR 5.53
- 52 Week Low
- HOND $9.97
- NKTR $0.42
- 52 Week High
- HOND $11.01
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- HOND N/A
- NKTR 43.94
- Support Level
- HOND N/A
- NKTR $1.33
- Resistance Level
- HOND N/A
- NKTR $1.43
- Average True Range (ATR)
- HOND 0.00
- NKTR 0.09
- MACD
- HOND 0.00
- NKTR -0.01
- Stochastic Oscillator
- HOND 0.00
- NKTR 23.21
About HOND HCM II ACQUISITION CORP
HCM II Acquisition Corp is a blank check company.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.